晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02228 晶泰控股

未开盘 05-18 16:08:29

8.170

-0.010

-0.12%

最高8.200	最低7.880	成交量5,137万
今开8.070	昨收8.180	日振幅3.91%
总市值351.56亿	流通市值351.56亿	总股本43.03亿
成交额4.13亿	换手率1.19%	流通股本43.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02228","market":"HK","secType":"STK","nameCN":"晶泰控股","latestPrice":8.17,"timestamp":1779091709004,"preClose":8.18,"halted":0,"volume":51373041,"delay":0,"changeRate":-0.0012224938875305363,"floatShares":4303000000,"shares":4303000000,"eps":0.03455298622585217,"marketStatus":"未开盘","change":-0.01,"latestTime":"05-18 16:08:29","open":8.07,"high":8.2,"low":7.88,"amount":413242726,"amplitude":0.03912,"askPrice":8.17,"askSize":155000,"bidPrice":8.16,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.03455298622585217,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779154200000},"marketStatusCode":0,"adr":0,"listingDate":1718208000000,"exchange":"SEHK","adjPreClose":8.18,"openAndCloseTimeList":[[1779067800000,1779076800000],[1779080400000,1779091200000]],"volumeRatio":0.9938781157755093,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02228","defaultTab":"news","newsList":[{"id":"2636304327","title":"“2026智通财经夏季路演大会”活动报名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636304327?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["03317","03858","02655","08299","02726","VXUS","01021","02729","01378","02670","01333","01907","02706","02650","02411","00363","00826","01300","00400","02685","06051","06682","02659","02565","02575","03881","02889","02228","06090","02675","02142","BK1155","LU0314109678.HKD","00650","BK1100","01396","02652","BK1171","00305","06651","01384","02623","02526","HK0001040143.USD","LU0287142896.SGD","00290","09696","06938","06636","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633687104","title":"【券商聚焦】中国银河：医药行业进入复苏周期 CXO板块景气度较高","url":"https://stock-news.laohu8.com/highlight/detail?id=2633687104","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633687104?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:00","pubTimestamp":1778202049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中国银河证券表示，2025年医药行业上市公司营业收入增长0.4%，归母净利润增长3.9%，扣非净利润下降4.1%，2026年一季度营业收入增长1.1%，归母净利润下降3.2%，扣非净利润增长2.0%。2025全年医药行业收入端小幅微增，主要系医保控费趋严，仿制药、耗材等集采常态化开展导致行业承压。2026年一季度创新药产业链高景气度延续，收入增幅扩大、非经常性损益占比下降，行业整体经营盈利能力提升，进入复苏上行周期。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ZDNhNDUwNDVmY2U2MTcxMzU2NTcyMzcyOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980878","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU0588546209.SGD","09926","BK1585","LU0561508036.HKD","LU1961090484.USD","BK1583","06160","LU0640798160.USD","02228","LU1303224171.USD","LU0634319403.HKD","BK1141","CXO","LU0417516902.SGD","03933","LU0348766576.USD","BK1207","LU1969619763.USD","06881","BK1161","06821","LU2778985437.USD","BK1588","LU0348767384.USD","LU1794554557.SGD","LU0348783233.USD","LU1719994722.HKD","LU2488822045.USD","BK1197","LU0348735423.USD","IE00BPRC5H50.USD","BK0188","01789","LU0417516571.SGD","09688","02196","BK1593","LU2328871848.SGD","01530","02367","BK0276","LU0307460666.USD","LU0417516738.SGD","BK1500","02268","01099","601881","LU1251922891.USD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175745145","title":"晶泰控股更新4月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1175745145","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175745145?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:42","pubTimestamp":1778143360,"startTime":"0","endTime":"0","summary":"晶泰控股于2026年5月7日提交的股份变动月报表显示，截至2026年4月30日，公司股本结构保持稳定，已发行股份维持在4,303,371,761股，库藏股数量为0股。公司法定/注册股本总额为1,000,000美元，股本面值为每股0.00001美元，本月内并无增加或减少。根据月报表，公司在报告期内未进行新的股份发行、购回及注销，整体已发行股本总数与上个月相同。公司本次月报由晶泰控股董事温书豪博士签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176808963","title":"晶泰控股(02228) 斥资3.56亿元再购浦发银行结构性存款，12个月累计规模约8.73亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176808963","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176808963?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:15","pubTimestamp":1777986957,"startTime":"0","endTime":"0","summary":"晶泰控股5月5日在港交所公告，旗下全资子公司QuantumPharm Limited已于2025年9月11日动用闲置资金人民币3.56亿元，认购上海浦东发展银行发行的两款低风险、保本浮动收益型结构性存款产品。连同过去12个月内已完成的六笔同类认购，公司在向浦发银行认购结构性存款上的累计交易金额达到约8.73亿元。值得关注的是，公司此前在认购浦发银行结构性存款时未及时发布公告。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633945627","title":"晶泰控股(02228)附属3.561亿元购买若干浦发银行结构性存款","url":"https://stock-news.laohu8.com/highlight/detail?id=2633945627","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633945627?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:15","pubTimestamp":1777986905,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股 发布公告，于2025年9月11日，公司的附属公司QuantumPharm Limited以总对价人民币3.561亿元购买若干由上海浦东发展银行股份有限公司发行的结构性存款。浦发银行结构性存款为保本型产品，设有最低保证回报，另加浮动回报。发行人浦发银行为中国知名银行。因此，董事认为该等交易乃按一般商业条款进行，属公平合理，并符合公司及股东的整体利益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0278","600000","BK0086","BK0201","BK0187","LU1808992512.USD","BK0183","SGXZ49509284.SGD","02228","SGXZ81163826.USD","LU1934453819.USD","BK1141","BK1617","LU0469268626.HKD","BK0028","BK0015","LU1979443071.USD","BK0188","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631356119","title":"港股异动 | 晶泰控股(02228)尾盘涨逾8% 全球首创泛TEAD抑制剂亮相2026广东人工智能大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2631356119","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631356119?lang=zh_cn&edition=full","pubTime":"2026-04-29 15:17","pubTimestamp":1777447020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，晶泰控股尾盘涨逾8%，截至发稿，涨8.14%，报9.17港元，成交额5.37亿港元。据悉，SIGX2649 为潜在first-in-class/best-in-class的泛TEAD抑制剂，在实体瘤治疗领域有广泛的药物市场。TEAD抑制剂作为靶向HIPPO通路的核心靶点，临床前数据显示，SIGX2649能有效抑制四种TEAD亚型，具备更强抗肿瘤活性、更低肾毒性，联用潜力突出，全球尚无同靶点药物上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1617","BK4077","BK4585","AGIX","VXUS","161631","02228","BK1141","ARTY","CHAT","TEAD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165941444","title":"异动解读 | 晶泰控股盘中大涨5.07%，年报利好兑现回调后迎来反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1165941444","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165941444?lang=zh_cn&edition=full","pubTime":"2026-04-29 14:39","pubTimestamp":1777444797,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中大涨5.07%，引起了市场的广泛关注。消息面上，公司此前披露的年度业绩表现强劲，收入同比增长逾两倍，并首次实现年度盈利。股价在业绩公布后因“利好兑现”及卖空压力经历了连续回调，今日盘中出现放量反弹，市场情绪因此得到修复。行业层面，生命科学工具和服务板块表现出现分化，同属AI制药赛道的部分公司股价也有所上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184562296","title":"异动解读 | 晶泰控股盘中大跌6.45%，年报利好兑现后承压，行业板块走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1184562296","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184562296?lang=zh_cn&edition=full","pubTime":"2026-04-24 09:56","pubTimestamp":1776995813,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中大跌6.45%，引起了市场的关注。消息面上，公司此前披露了年度业绩，收入同比增长逾两倍，并首次实现年度盈利。然而，股价在业绩公布后持续回落，呈现出“利好兑现”后的承压态势。同时，近期市场卖空活动活跃，空头成交金额占比较高，反映了部分资金的看空情绪。此外，从行业层面看，生命科学工具和服务板块整体表现疲软，晶泰控股在板块内领跌，行业环境的走弱也对股价构成了压力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115956576","title":"晶泰控股（02228）2025年收入大增并实现扭亏 AI与药物研发协同驱动业务突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1115956576","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115956576?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:01","pubTimestamp":1776430883,"startTime":"0","endTime":"0","summary":"于截至2025年12月31日止年度，晶泰控股收入达人民币8.03亿元，较上一年度的2.66亿元同比增长逾两倍。集团年内利润成功扭转2024年亏损15.15亿元的局面，实现人民币1.35亿元的正向收益，其中归属于公司权益持有人的利润为1.24亿元。主要收入来源包括药物发现解决方案和AI for Science智能化解决方案，两大板块分别实现418.9%和62.6%的增长，为整体业绩带来显著提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628209458","title":"晶泰控股(02228)建议采纳一项新股份计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2628209458","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628209458?lang=zh_cn&edition=full","pubTime":"2026-04-17 20:51","pubTimestamp":1776430267,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股(02228)公布，董事会建议采纳一项新股份计划，以进一步使公司董事及雇员的长期利益与公司的长期利益保持一致，并激励彼等持续推动公司的增长及发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627328922","title":"“AI制药第一股”晶泰科技进驻广州天河","url":"https://stock-news.laohu8.com/highlight/detail?id=2627328922","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627328922?lang=zh_cn&edition=full","pubTime":"2026-04-15 19:30","pubTimestamp":1776252617,"startTime":"0","endTime":"0","summary":"4月15日，AI制药领军企业、“AI制药第一股”晶泰科技正式进驻广州天河的广电平云广场，同时与广州数字科技集团、广东创新投资发展有限公司完成战略签约，共同推动医疗数据与垂类大模型在生物医药领域深度应用。同日，平云OPC创新社区挂牌。晶泰科技由三位麻省理工学院的物理学家于2015年创立，是全球领先的以AI与机器人自动化实验技术驱动研发创新的平台型企业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153706140328.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153706140328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","AGIX","BK1141","BK1191","CHAT","02228","BK1617","AIPO","ARTY","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159698623","title":"异动解读 | 机构研报梳理AI制药核心价值，晶泰控股盘中大涨5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159698623","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159698623?lang=zh_cn&edition=full","pubTime":"2026-04-15 09:41","pubTimestamp":1776217282,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中大幅上涨5.48%，引起市场关注。消息面上，近期有机构发布深度研报，系统性地梳理了公司的核心价值。报告指出，晶泰控股在AI制药领域具有前瞻性布局和技术优势，其构建的“量子物理+AI+机器人实验”三位一体全链条技术闭环，以及较高的商业化项目兑现率，为公司基本面提供了有力支撑，这或是推动股价走强的主要原因。此外，公司在融资、实验效率及中长期打造AI for Science通用研发平台的目标方面表现突出，增强了市场对其未来增长潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626135899","title":"晶泰控股(02228)授出合共1123.43万购股权及1092.08万个受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2626135899","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626135899?lang=zh_cn&edition=full","pubTime":"2026-04-09 22:32","pubTimestamp":1775745144,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股(02228)发布公告，于2026年4月9日，本公司根据购股权计划的条款向137名承授人授出合共1123.43万购股权及根据受限制股份单位计划的条款向270名承授人授出合共1092.08万个受限制股份单位，惟各自须待接纳后方可作实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1617","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106286256","title":"晶泰控股更新3月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1106286256","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106286256?lang=zh_cn&edition=full","pubTime":"2026-04-08 16:36","pubTimestamp":1775637385,"startTime":"0","endTime":"0","summary":"晶泰控股有限公司于2026年4月8日发布2026年3月股份变动月报表，报告期截至2026年3月31日。根据公告，法定股本保持在100,000,000,000股，面值每股USD 0.00001，对应总额USD 1,000,000；已发行股份数亦维持在4,303,371,761股，无任何新增发行或回购注销情况。根据月报披露，报告期内并无股份发行、购回或库藏股变动。公司同时确认已符合香港联交所对于上市公司公众持股量的要求。公司强调将继续遵守香港联交所《上市规则》及相关法律规定，当前股本结构保持稳定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623373124","title":"【券商聚焦】中信证券：基本医保基金收支和结余整体保持稳健","url":"https://stock-news.laohu8.com/highlight/detail?id=2623373124","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623373124?lang=zh_cn&edition=full","pubTime":"2026-03-31 08:59","pubTimestamp":1774918794,"startTime":"0","endTime":"0","summary":"2026年2月医保支出同比增速回升，收支剪刀差有所收窄。该机构预计在医保基金监管力度持续加大，DRG/DIP精细化管理的推动下，2026年全年基金结余率或将延续此前节奏略有提升。医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977773","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","03933","LU1115378108.SGD","LU0405327494.USD","02367","HK0000165453.HKD","BK1583","LU1255011170.USD","LU2148510915.USD","BK1593","LU1303224171.USD","06160","LU1328615791.USD","BK0012","IE00B543WZ88.USD","LU2476274308.USD","LU2495084118.USD","BK1564","LU1770034418.SGD","01099","BK1588","LU0405327148.USD","LU0634319403.HKD","LU2399975544.HKD","BK0028","06821","09926","BK1515","LU0348766576.USD","01530","09688","LU2488822045.USD","BK0276","01789","02228","LU0307460666.USD","600030","06030","LU1719994722.HKD","LU0348735423.USD","02196","LU0348783233.USD","LU1969619763.USD","BK1161","IE00BPRC5H50.USD","BK1100","LU1997245177.USD","BK1147","02268","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622446802","title":"如何解读晶泰控股这份“扭亏为盈”财报？","url":"https://stock-news.laohu8.com/highlight/detail?id=2622446802","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622446802?lang=zh_cn&edition=full","pubTime":"2026-03-28 10:46","pubTimestamp":1774666016,"startTime":"0","endTime":"0","summary":"3月25日，中国AI制药“第一股”晶泰控股披露了2025年全年业绩公告，交出了一份亮眼的“扭亏”答卷。今天，我们将从纯财务视角出发，层层拆解，还原晶泰控股“扭亏为盈”的真实面貌。这笔 5100 万美元首付款，成为晶泰控股实现 “扭亏” 的重要支撑，而 4900 万美元里程碑款并未计入本次财报。02 核心主业持续向好尽管晶泰控股本次扭亏并非依靠持续经营业务驱动，但其核心业务基本面确实呈现持续向好态势。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1774582771818978437","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2622281595","title":"晶泰控股2025年营收8亿：经营利润5524万 刚发行29亿港元债券","url":"https://stock-news.laohu8.com/highlight/detail?id=2622281595","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622281595?lang=zh_cn&edition=full","pubTime":"2026-03-27 09:41","pubTimestamp":1774575672,"startTime":"0","endTime":"0","summary":"晶泰控股有限公司（简称：“晶泰控股”，股票代码：“2228”）日前发布截至2025年12月31日的财报。财报显示，晶泰控股2025年营收为8亿元，较上年同期的2.66亿元增长201%。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260327/6391020126839380581981730.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260327/6391020126839380581981730.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33072/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622285725","title":"晶泰科技2025年年报出炉：首次盈利，AI for Science进入价值兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622285725","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622285725?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:18","pubTimestamp":1774527517,"startTime":"0","endTime":"0","summary":"3月25日晚，晶泰控股（2228.HK）发布2025年全年业绩报告。数据显示，公司全年营收达8.03亿元，同比增加201.2%。报告期内，公司首次实现年度盈利，也成为AI应用领域率先盈利的港股上市公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263685820583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1617","CHAT","AIPO","AGIX","BK1141","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622783996","title":"“AI制药”的晶泰控股扭亏虚与实","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783996","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622783996?lang=zh_cn&edition=full","pubTime":"2026-03-26 14:52","pubTimestamp":1774507932,"startTime":"0","endTime":"0","summary":"港股“AI制药明星企业”晶泰控股交出了上市以来的首份扭亏答卷。\n2025年，晶泰控股实现营业收入8....","market":"hk","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3768447","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“AI制药”的晶泰控股扭亏虚与实","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHAT","02228","BK1141","AGIX","01477","BK1617","BK1574","BK1191","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173204622","title":"异动解读 | 晶泰控股盘中大涨5.18%，首次全年盈利及AI平台商业化进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1173204622","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173204622?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:38","pubTimestamp":1774489112,"startTime":"0","endTime":"0","summary":"晶泰控股今日盘中大涨5.18%，引起了市场的广泛关注。消息面上，公司于3月25日发布了2025年年度业绩报告，首次实现全年盈利，成为AI for Science领域首家盈利的港股上市公司。同时，晶泰控股近期与DoveTree达成了一项总订单规模约470亿港元的管线合作，并获得了约4亿港元首付款，创下了人工智能新药研发领域订单规模的新纪录。公司还在大分子药物研发领域与礼来达成总额达3.45亿美元的多靶点战略合作及平台授权协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"e1d988722ff66852c525a3ca4fcad38d","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.xtalpi.com","stockEarnings":[{"period":"1week","weight":-0.11},{"period":"1month","weight":-0.1959},{"period":"3month","weight":-0.2738},{"period":"6month","weight":-0.1951},{"period":"1year","weight":0.8912},{"period":"ytd","weight":-0.1364}],"compareEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0185},{"period":"3month","weight":-0.0386},{"period":"6month","weight":-0.006},{"period":"1year","weight":0.0998},{"period":"ytd","weight":0.0017}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。该公司主要经营两个业务。药物发现解决方案业务从事就新型药物发现工作为各类生物技术与制药公司和学术机构提供模块独立解决方案或与之合作。智能自动化解决方案业务从事提供固态研发服务及自动化化学合成服务。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.06643},{"month":2,"riseRate":0.285714,"avgChangeRate":0.016028},{"month":3,"riseRate":0,"avgChangeRate":-0.069153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.048494},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010585},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.023767},{"month":7,"riseRate":0.428571,"avgChangeRate":0.047576},{"month":8,"riseRate":0.5,"avgChangeRate":-0.032189},{"month":9,"riseRate":0.8,"avgChangeRate":0.065839},{"month":10,"riseRate":0.6,"avgChangeRate":0.092453},{"month":11,"riseRate":0.5,"avgChangeRate":0.05299},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011625}],"exchange":"SEHK","name":"晶泰控股","nameEN":"XTALPI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"晶泰控股,02228,晶泰控股股票,晶泰控股股票老虎,晶泰控股股票老虎国际,晶泰控股行情,晶泰控股股票行情,晶泰控股股价,晶泰控股股市,晶泰控股股票价格,晶泰控股股票交易,晶泰控股股票购买,晶泰控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}